Novartis Agreement - Additional Information (Details) $ in Millions			6 Months Ended
	Feb. 28, 2021 USD ($)	Jun. 28, 2019 USD ($) License shares	Jun. 30, 2024 USD ($) License	Dec. 31, 2023 shares	Feb. 24, 2021 shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
License Agreement [Line Items]
Preferred stock, shares issued | shares				0
Novartis Agreement | Novartis
License Agreement [Line Items]
Number of licensed Product | License		1
Upfront cash payment		$ 0.4
Total initial consideration transferred		3.4
Aggregate milestone payments		231.7
Number of development milestone payments | License			2
Development milestone payments			$ 1.0
Milestone payments achieved and paid						$ 0.6	$ 0.4
Novartis Agreement | Novartis | Research and Development Expense
License Agreement [Line Items]
Initial fair value of anti-dilution right liability		$ 1.0
Novartis Agreement | Series A-1 Preferred Stock | Maximum
License Agreement [Line Items]
Preferred stock, shares issued | shares		6,383,142
Novartis Agreement | Series A-1 Preferred Stock | Novartis
License Agreement [Line Items]
Preferred stock, shares issued | shares		3,449,808
Fair value of stock		$ 3.0
Ownership interest		15.00%
Licensing milestone in sales of equity securities	$ 30.0	$ 30.0
Novartis Agreement | Series A-1 Preferred Stock | Novartis | Minimum
License Agreement [Line Items]
Licensing milestone in sales of equity securities		$ 30.0
Novartis Agreement | Series A-1 Preferred Stock | Novartis | Maximum
License Agreement [Line Items]
Preferred stock, shares issued | shares					5,970,000